<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20DEC47C-C2A6-434D-8808-69154518345B"><gtr:id>20DEC47C-C2A6-434D-8808-69154518345B</gtr:id><gtr:name>Cambridge Research Biochemicals</gtr:name><gtr:address><gtr:line1>10 Belasis Court</gtr:line1><gtr:line2>Belasis Hall Technology Park</gtr:line2><gtr:postCode>TS23 4AZ</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/95FFCF2B-A81C-4BA5-BCCF-A07EE98D14AD"><gtr:id>95FFCF2B-A81C-4BA5-BCCF-A07EE98D14AD</gtr:id><gtr:name>Panagene</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/728EA6EA-26D9-4D12-B232-F857FF738811"><gtr:id>728EA6EA-26D9-4D12-B232-F857FF738811</gtr:id><gtr:name>Link Technologies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355"><gtr:id>8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355</gtr:id><gtr:name>European Cooperation in Science and Technology (COST)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/732C4730-B975-48A4-8B00-F5769C7D79B6"><gtr:id>732C4730-B975-48A4-8B00-F5769C7D79B6</gtr:id><gtr:name>Alnylam Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/518EDA6E-FB2B-4922-9AED-DD9983C57081"><gtr:id>518EDA6E-FB2B-4922-9AED-DD9983C57081</gtr:id><gtr:name>Activotec SPP</gtr:name><gtr:address><gtr:line1>Activotec SPP</gtr:line1><gtr:line2>University of Southampton</gtr:line2><gtr:line3>Biomedical Sciences Bldg, Basset Cres. E</gtr:line3><gtr:postCode>SO16 7PX</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20DEC47C-C2A6-434D-8808-69154518345B"><gtr:id>20DEC47C-C2A6-434D-8808-69154518345B</gtr:id><gtr:name>Cambridge Research Biochemicals</gtr:name><gtr:address><gtr:line1>10 Belasis Court</gtr:line1><gtr:line2>Belasis Hall Technology Park</gtr:line2><gtr:postCode>TS23 4AZ</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/95FFCF2B-A81C-4BA5-BCCF-A07EE98D14AD"><gtr:id>95FFCF2B-A81C-4BA5-BCCF-A07EE98D14AD</gtr:id><gtr:name>Panagene</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/728EA6EA-26D9-4D12-B232-F857FF738811"><gtr:id>728EA6EA-26D9-4D12-B232-F857FF738811</gtr:id><gtr:name>Link Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355"><gtr:id>8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355</gtr:id><gtr:name>European Cooperation in Science and Technology (COST)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/732C4730-B975-48A4-8B00-F5769C7D79B6"><gtr:id>732C4730-B975-48A4-8B00-F5769C7D79B6</gtr:id><gtr:name>Alnylam Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/518EDA6E-FB2B-4922-9AED-DD9983C57081"><gtr:id>518EDA6E-FB2B-4922-9AED-DD9983C57081</gtr:id><gtr:name>Activotec SPP</gtr:name><gtr:address><gtr:line1>Activotec SPP</gtr:line1><gtr:line2>University of Southampton</gtr:line2><gtr:line3>Biomedical Sciences Bldg, Basset Cres. E</gtr:line3><gtr:postCode>SO16 7PX</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/117CE4DE-3A10-4A07-89DD-E3BD8F8FA6BC"><gtr:id>117CE4DE-3A10-4A07-89DD-E3BD8F8FA6BC</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Gait</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U105178803"><gtr:id>72EA8F86-51A9-4F6F-8F0A-CA3F1D6909FD</gtr:id><gtr:title>Applications of synthetic nucleic acids and their peptide conjugates</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U105178803</gtr:grantReference><gtr:abstractText>Most clinically used drugs are small molecules targeted to inhibit the action of an essential protein. A new approach in drug development is to target the genetic material in a cell (nucleic acid) that codes for such proteins, of which the most readily accessible is ribonucleic acid (RNA). Short pieces of synthetic nucleic acid (oligonucleotides, ONs) are used to form complementary base pairs with RNA inside cells (antisense) so as to block its ability to express a protein or carry out a regulatory function. For therapeutic use, ONs are chemically modified to prevent degradation by enzymes in blood and in cells and to slow clearance from the body. Modified ONs are being used clinically and are in clinical trials for treatment of viral infections, obesity, inflammation, cancer and genetic diseases. One problem is that ONs do not enter most human cells efficiently. Our research involves chemical synthesis of ON analogues and their peptide conjugates designed to improve cell uptake and RNA targeting efficiency as well as efficacy in mouse models of disease in partnership with collaborators in Oxford. Particular effort is focussed on peptide nucleic acids (PNA) and phosphorodiamidate morpholino ONs (PMO), ON analogues that are charge neutral. PNA and PMO ON types bind strongly to complementary RNA with high sequence specificity. We attach to PNA and PMO short novel peptides (protein segments) that have cell penetrating properties. We are applying such antisense ONs and their peptide conjugates to redirect pre-messenger RNA splicing in the nucleus of cells. We focus in particular on developing ON-based strategies towards developing new therapeutic leads for treatment of hitherto incurable neuromuscular genetic diseases, such as Duchenne muscular dystrophy, spinal muscular atrophy and myotonic dystrophy. In conjunction with colleagues at Oxford University we hope to take lead peptide-PMO conjugates towards clinical trials in one or more of these diseases.</gtr:abstractText><gtr:technicalSummary>Short synthetic oligonucleotides (ONs) and their analogues are used extensively to inhibit gene expression in cells and as potential therapeutics. ONs bind complementary RNA and either sterically block an essential RNA function or induce the cleavage of the RNA by a cellular enzyme RNase H. ONs must be able to penetrate the desired cells (in culture or in vivo), reach their RNA targets in the cytosol or nucleus, and bind specifically to the correct RNA site. We utilize ONs that carry modifications to help RNA binding and to resist degradation by cellular and serum nucleases. However, ONs are generally poor in cell penetration. Our research focuses on the chemical synthesis of ON analogues as conjugates with synthetic peptides that show enhanced cell delivery properties in the absence of additional carriers (e.g. cationic lipids, nanoparticles). A major part of current work focuses on peptide conjugates of charge-neutral ON analogues, peptide nucleic acids (PNA) and phosphorodiamidate morpholino oligonucleotides (PMO). We designed a novel class of cell penetrating peptides (CPPs) called Pip that have increased serum stability and when linked to PNA or PMO act as steric blocking agents to redirect splicing of pre-mRNA with excellent efficiencies. We have used Pip conjugates of PMO ONs targeting exon 23 of the dystrophin gene in a mdx mouse model of Duchenne Muscular Dystrophy (DMD). In collaboration with the group of Matthew Wood in Oxford, we obtained substantially enhanced exon skipping and dystrophin production in vivo compared to naked PMO. We have since developed further peptide classes as PMO conjugates with high activity in the mdx mouse model that are suitable as clinical leads for treatment of DMD patients. This work has been extended to obtain high activity for novel peptide conjugates of PMO in mouse models of other neuromuscular diseases, namely spinal muscular atrophy (SMA) and myotonic dystrophy. We hope to exploit these leads through establishment of a joint MRC-Oxford spln-off company.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>5278377</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cambridge Research Biochemicals</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CRB License and collaboration</gtr:description><gtr:id>210EC15C-57E4-433D-B8B7-024E48CACBF9</gtr:id><gtr:impact>Patent application</gtr:impact><gtr:outcomeId>PnuxZtGFvYB-1</gtr:outcomeId><gtr:partnerContribution>Licensing of patent application and development of synthesis service for customers</gtr:partnerContribution><gtr:piContribution>Development of synthesis method for preparation of libraries of peptide conjugates of biocargoes</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>MDEX clinical consortium</gtr:description><gtr:id>94D4DCCA-7CD6-4CD4-A9A8-EC20534692A9</gtr:id><gtr:impact>Grants awarded from the Wellcome Trust and the AFM began 2011</gtr:impact><gtr:outcomeId>MBKBDWfykBK-1</gtr:outcomeId><gtr:partnerContribution>Grants awarded Wellcome/AFM</gtr:partnerContribution><gtr:piContribution>Joint work and grant applications on Duchenne muscular dystrophy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MedImmune</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Astra-Zeneca/LMB joint grant</gtr:description><gtr:id>99A70174-2B03-417C-B495-BB3979BB8D5A</gtr:id><gtr:impact>Chemistry and cell testing from LMB. Antibodies from Medimmune.</gtr:impact><gtr:outcomeId>56dd9f8ee04156.96815261-1</gtr:outcomeId><gtr:partnerContribution>Provision of antibodies</gtr:partnerContribution><gtr:piContribution>Blue-skies research project providing 9 months salary and overheads to</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alnylam Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SiRNA testing</gtr:description><gtr:id>C2ADD3E4-3143-4984-AB06-5240A2E7B935</gtr:id><gtr:impact>Material Transfer Agreement (MTA) - Double luciferase test cell line</gtr:impact><gtr:outcomeId>C77D8144C09-1</gtr:outcomeId><gtr:partnerContribution>Received test cell line from Alnylam for siRNA testing. Used and reported in talks, but not published in detail</gtr:partnerContribution><gtr:piContribution>Received test cell line from Alnylam for siRNA testing. Used and reported in talks, but not published in detail</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Activotec SPP</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Peptide synthesizer</gtr:description><gtr:id>1A91AF1A-C4E1-4402-83B1-0CCDCF182253</gtr:id><gtr:impact>Some initial collaboration in developing new peptide synthesiser and short term evaluation. project terminated</gtr:impact><gtr:outcomeId>78AD2C93ED3-1</gtr:outcomeId><gtr:partnerContribution>Some initial collaboration in developing new peptide synthesiser and short term evaluation. project terminated</gtr:partnerContribution><gtr:piContribution>Development of Activotec peptide synthesizer with help from staff member David Owen</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Link Technologies</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Sample Materials from Link</gtr:description><gtr:id>5815D01A-38C1-4CEA-8772-078DA10304DD</gtr:id><gtr:impact>Receipt of sample materials for oligonucleotide and PNA synthesis</gtr:impact><gtr:outcomeId>A7F06E965DB-1</gtr:outcomeId><gtr:partnerContribution>Receipt of sample materials for oligonucleotide and PNA synthesis</gtr:partnerContribution><gtr:piContribution>MRC license income from patent assignment.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EU FP5 Consortium</gtr:description><gtr:id>04F4943E-5FF0-44D7-930F-239E4D9047B1</gtr:id><gtr:impact>Exchange of ideas, materials and joint publications.</gtr:impact><gtr:outcomeId>E01BC93C4FE-1</gtr:outcomeId><gtr:partnerContribution>Exchange of ideas, materials and joint publications. Consultancy</gtr:partnerContribution><gtr:piContribution>Part of EU FP5 consortium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Cooperation in Science and Technology (COST)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>EU COST programme BM 1207</gtr:description><gtr:id>F64FE039-DA0C-4A0A-88BD-C9A9BD33A9D5</gtr:id><gtr:impact>multi-disciplinary collaboration</gtr:impact><gtr:outcomeId>545377258957c0.47788555-1</gtr:outcomeId><gtr:partnerContribution>Presentations and discussions</gtr:partnerContribution><gtr:piContribution>Presentations and discussions to a large range of EU research groups involved in exon skipping of pre-mRNA</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Experimental Medicine</gtr:department><gtr:description>Development of PNA Synthesizer</gtr:description><gtr:id>C650CB4E-07B1-4161-A6CD-8670E4CEA562</gtr:id><gtr:impact>Co-development of equipment and method for PNA synthesis. Paper to be submitted Dec 2009</gtr:impact><gtr:outcomeId>9B307E7D760-1</gtr:outcomeId><gtr:partnerContribution>co-development of equipment for PNA synthesis</gtr:partnerContribution><gtr:piContribution>Initial discussion about collaboration was followed by agreement to collaborate</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Panagene</gtr:collaboratingOrganisation><gtr:country>Korea, Republic of</gtr:country><gtr:description>EU FP5 Consortium</gtr:description><gtr:id>764196F2-FE89-44A6-B6F7-4524AA8809FA</gtr:id><gtr:impact>Exchange of ideas, materials and joint publications.</gtr:impact><gtr:outcomeId>E01BC93C4FE-2</gtr:outcomeId><gtr:partnerContribution>Exchange of ideas, materials and joint publications. Consultancy</gtr:partnerContribution><gtr:piContribution>Part of EU FP5 consortium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Action Duchenne Conference 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8940ADBD-9E37-4FCF-96D1-AECBCE35C196</gtr:id><gtr:impact>Interest in our research from funders, companies and patient groups

Awareness of our pre-clinical and clinical collaborative drug development programmes</gtr:impact><gtr:outcomeId>545378f63ca781.93852450</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Action Duchenne Conference 2009</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>80B98A21-C889-45EC-A8AA-8B88EDF34DF2</gtr:id><gtr:impact>gave a lecture

further funding from Action Duchenne</gtr:impact><gtr:outcomeId>4E96B66E84A</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Media Centre Press briefing</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DBA57775-CE77-4834-931D-5E7F86A5FB52</gtr:id><gtr:impact>10 min talk to journalists about recent developments in therapeutics of RNA interference

no further interviews took place but name more widely known</gtr:impact><gtr:outcomeId>E295AD6D620</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LMB alumni symposium</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>24056C0C-062E-470C-B98E-A13F802E979A</gtr:id><gtr:impact>Many visits by alumni to our research group and viewing of poster

greater awareness of research of group</gtr:impact><gtr:outcomeId>54537a5c327c99.95939563</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit Swedish PhD Group</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4DECB320-4B42-4A42-896D-D7F9FACDF66D</gtr:id><gtr:impact>Visit of about 20 Swedish Ph D students to LMB to see what is involved in postdoctoral research

Potential applicants for future postdoc positions</gtr:impact><gtr:outcomeId>sNqXcmzqZ7C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Action Duchenne conference 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CBADD700-A9C6-48E8-945A-B8C77CFD8917</gtr:id><gtr:impact>gave talk

further funding opportunities</gtr:impact><gtr:outcomeId>HX9KjF4yaqN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Action Duchenne Conference 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>25B8170B-9EA9-452A-9E86-609350CBD4D4</gtr:id><gtr:impact>gave talk

company interest in our work for possible collaboration</gtr:impact><gtr:outcomeId>MMX2VShwzQm</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Action Duchenne Conference 2008</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>29E20E83-31AE-4690-9172-F3F7294B8484</gtr:id><gtr:impact>Gave a lecture about my research

Funding received from Action Duchenne towards research</gtr:impact><gtr:outcomeId>73912AE2944</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview BBC Radio Camb</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>165E2E4C-6A1A-4D0D-87BF-88E349EC52BD</gtr:id><gtr:impact>6 min radio interview BBC radio Cambridgeshire 07.45 regarding my comments on a scientific paper from another lab and mentioning our own work in relation

No further outcome</gtr:impact><gtr:outcomeId>A7EFAD66599</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dutch Undergraduates visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1A81662D-F3C9-4332-874E-7E76CAD713D6</gtr:id><gtr:impact>Visit of 6 students from Radboud Honours Academy, Radboud University, The Netherlands, who were studying muscular dystrophies. Gave them a talk about research careers in the MRC.

Interest from one student in potential research</gtr:impact><gtr:outcomeId>SokJNUrhYqL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3982</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society Award-Tandon</gtr:description><gtr:end>2007-12-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>69CF9553-9DBC-4FC4-91D4-12CB2A2265C0</gtr:id><gtr:outcomeId>C98A2A42FEB0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>313668</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>AUD</gtr:currCode><gtr:currCountryCode>Australia</gtr:currCountryCode><gtr:currLang>en_AU</gtr:currLang><gtr:department>National Health and Medical Research Council</gtr:department><gtr:description>NHMRC Early Career Fellowship</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Australian Government</gtr:fundingOrg><gtr:id>E2821CB4-61E9-4E5B-9B2B-A95A674E637C</gtr:id><gtr:outcomeId>545b6f7e8bf621.49791208</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>175234</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DoH/WT Health Innovation Challenge Fund</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>R15741/DPAG/Wood</gtr:fundingRef><gtr:id>0A87B35F-A5C2-4381-8415-E2042088E811</gtr:id><gtr:outcomeId>Neq68xgx5Dj1</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>198658</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>AFM Research Project</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>95E25939-78B2-40B9-8CB1-B324D049D2FB</gtr:id><gtr:outcomeId>545b6e37072406.84461747</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Action Duchenne</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>Action Duchenne</gtr:fundingOrg><gtr:id>B7F6D23F-415C-4C14-B73F-EE571C9D69B4</gtr:id><gtr:outcomeId>03044682E870</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Darwin Trust of Edinburgh</gtr:department><gtr:description>Cesar Milstein Studentship</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>British Society for the History of Science (BSHS)</gtr:fundingOrg><gtr:id>2569670A-656A-497E-8859-B0B0955284E4</gtr:id><gtr:outcomeId>qvq8rHuHo93</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>LMB/AztraZeneca Blue Skies Initiative</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>D8BAE265-1043-4BB1-A573-328C1278E8AA</gtr:id><gtr:outcomeId>58b03175055826.70546400</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65153</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRCT Development Gap Funding</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>843CF514-E8FB-495B-915D-A471CECEAAAD</gtr:id><gtr:outcomeId>0D23B406E4C0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>243425</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Fifth Framework Programme (FP5)</gtr:department><gtr:description>EC FP5 shared costs</gtr:description><gtr:end>2006-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>B2C041D0-1B73-4879-B1E2-542F3A9155AC</gtr:id><gtr:outcomeId>466532FB1EC0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2003-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>188183</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L013142/1</gtr:fundingRef><gtr:id>C2916D3F-8CE4-474F-A923-24F08465F203</gtr:id><gtr:outcomeId>545b71ebeed213.75711450</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180848</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Development Gap Funding</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>A853-0132</gtr:fundingRef><gtr:id>6175DE58-E8B1-4D11-AA48-F4F5BA73885A</gtr:id><gtr:outcomeId>UK9BwNYTgHz0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22651</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Collaborative Projects</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>74FE3BB4-AE24-49A7-8B24-6725C427CBC0</gtr:id><gtr:outcomeId>2FCD134C24B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>73799</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>AstraZeneca/LMB Blue skies Initiative</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>CFC48722-41CC-4893-A0C6-ED17456D947C</gtr:id><gtr:outcomeId>56d9a04b1a3967.11912613</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>279754</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>AFM Research Project</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:fundingRef>AVRUBKO</gtr:fundingRef><gtr:id>CA219934-201E-479A-B3E6-31027C315B51</gtr:id><gtr:outcomeId>bjGbN556VAS0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A novel design for a cell penetrating peptide for conjugation to biologically active cargoes such as oligonucleotides and peptides. Particular applications shown to conjugation to charge-neutral PNA and PMO oligonucleotides</gtr:description><gtr:grantRef>MC_U105178803</gtr:grantRef><gtr:id>2838A2FB-31F5-428A-8351-AE59C3E2D7F8</gtr:id><gtr:impact>Peptide sequences known as Pip that can be used as a delivery system for transporting peptides or nucleic acids into cells. Original patent application applied for June 2008, issued Dec 2009. Non exclusive licensing to Shire Pharmaceuticals. Other licenses have been explored.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>083A21D6EB8</gtr:outcomeId><gtr:patentId>US 8,575,305 B2</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Cell Penetrating Peptide</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A second series of cell penetrating peptides known as Pip with activity in muscle and heart as conjugates of PMO oligonucleotides</gtr:description><gtr:grantRef>MC_U105178803</gtr:grantRef><gtr:id>057A8698-3F23-4C25-8C84-9B0FFE0218FD</gtr:id><gtr:impact>License includes reporting of data by licensee on toxicology of Pip-PMO in rats. Additional licenses have also been explored.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>54537e2f167630.69555311</gtr:outcomeId><gtr:patentId>US 9,302,014 B2</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Cell Penetrating Peptides having a central hydrophobic domain</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Sophos Therapeutics</gtr:companyName><gtr:description>As yet a paper company ready to exploit cell penetrating peptides for DMD and other diseases; NULL</gtr:description><gtr:id>27457468-A435-423E-9FD6-0A67DF719EA6</gtr:id><gtr:impact>The company was disbanded in 2011 as it was not regarded as serving a useful purpose</gtr:impact><gtr:outcomeId>7906FD86604</gtr:outcomeId><gtr:yearCompanyFormed>2008</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>F860006C-4D16-47E1-89F6-2BB2A85F6CCF</gtr:id><gtr:title>Phosphoramidites and solid supports based on N-substituted 2,4-dihydroxybutyramides: universal reagents for synthesis of modified oligonucleotides</gtr:title><gtr:parentPublicationTitle>Tetrahedron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23c6dcd946d57b5d7e43953543859669"><gtr:id>23c6dcd946d57b5d7e43953543859669</gtr:id><gtr:otherNames>Dioubankova N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:outcomeId>3FF703A299D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E29C9CA3-8CAF-44D3-AD8E-0D6471DF9E35</gtr:id><gtr:title>Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/657260e5076ba6423d7ba111f3b75899"><gtr:id>657260e5076ba6423d7ba111f3b75899</gtr:id><gtr:otherNames>Betts CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d9aa9a209e68.94789935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40604221-6A44-4613-A759-F68ED572B0F6</gtr:id><gtr:title>How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c0247455a00e50e0d2f8876b067d92"><gtr:id>90c0247455a00e50e0d2f8876b067d92</gtr:id><gtr:otherNames>Godfrey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56d9aa993355a3.14531998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1007E89C-9394-4346-86CA-31D1F0164C70</gtr:id><gtr:title>Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5cbf7dc26a737e3b68f235e753a64e8"><gtr:id>e5cbf7dc26a737e3b68f235e753a64e8</gtr:id><gtr:otherNames>J?rver P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_14217_27_23344079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B8D2FFD-0479-4EF4-AE38-919B75B740F7</gtr:id><gtr:title>miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71c13663cd7f25b4656bcd671aa8c3a7"><gtr:id>71c13663cd7f25b4656bcd671aa8c3a7</gtr:id><gtr:otherNames>Lagos D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>cX9EobajoYr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF3D7DD9-05E0-44C6-889F-DA9A899F736E</gtr:id><gtr:title>Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1c38eb6bb5510013b210c20c66d1adb"><gtr:id>d1c38eb6bb5510013b210c20c66d1adb</gtr:id><gtr:otherNames>Lu-Nguyen NB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>56dd9bca740160.62005958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8DBD76A-3DF7-4435-86EB-7AFFB41A564F</gtr:id><gtr:title>Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide.</gtr:title><gtr:parentPublicationTitle>RNA (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/867c939f222ffde45b5b4b00923eace1"><gtr:id>867c939f222ffde45b5b4b00923eace1</gtr:id><gtr:otherNames>Detzer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1355-8382</gtr:issn><gtr:outcomeId>E06C91F1EB2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACD22B3E-1942-4B26-AB03-74612B9B1D6A</gtr:id><gtr:title>Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Nucleic acid therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5cbf7dc26a737e3b68f235e753a64e8"><gtr:id>e5cbf7dc26a737e3b68f235e753a64e8</gtr:id><gtr:otherNames>J?rver P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2159-3337</gtr:issn><gtr:outcomeId>56d9aa99f3daa9.67481446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70143F41-35EE-4B9A-A03F-0B959BC46F3F</gtr:id><gtr:title>Enhanced splice correction by 3', 5'-serinol and 2'-(?-O-methylserinol) guarded OMe-RNA/DNA mixmers in cells.</gtr:title><gtr:parentPublicationTitle>Artificial DNA, PNA &amp; XNA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11aa6b5fe33ca569169b05455befa64c"><gtr:id>11aa6b5fe33ca569169b05455befa64c</gtr:id><gtr:otherNames>Kotikam V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1949-095X</gtr:issn><gtr:outcomeId>545b6641aa7457.62670826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AE7C136-7442-46F2-AD18-C231BAD53CBB</gtr:id><gtr:title>Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58167f6b50117655440b62f734850c9f"><gtr:id>58167f6b50117655440b62f734850c9f</gtr:id><gtr:otherNames>Lehto T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>545b64a6c36848.76766051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>976963F6-BCDD-4642-9461-CF5D8384A0FF</gtr:id><gtr:title>Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Nano letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3da82a2c3555614b11f8aa0ad48d123"><gtr:id>d3da82a2c3555614b11f8aa0ad48d123</gtr:id><gtr:otherNames>Ezzat K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1530-6984</gtr:issn><gtr:outcomeId>56d9aa9a4c3cc8.83419592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FD5FA5F-D6B9-491B-ABF8-B3F287E5466A</gtr:id><gtr:title>PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3da82a2c3555614b11f8aa0ad48d123"><gtr:id>d3da82a2c3555614b11f8aa0ad48d123</gtr:id><gtr:otherNames>Ezzat K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>D1A68251_9D1A68251_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83E2B644-A590-4F2F-92DA-F44EAD29D38F</gtr:id><gtr:title>Comparative studies of tricyclo-DNA- and LNA-containing oligonucleotides as inhibitors of HIV-1 gene expression.</gtr:title><gtr:parentPublicationTitle>Nucleosides, nucleotides &amp; nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/046e7a1192a14d70b68ca33d3ca39b7a"><gtr:id>046e7a1192a14d70b68ca33d3ca39b7a</gtr:id><gtr:otherNames>Ivanova G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-7770</gtr:issn><gtr:outcomeId>83A6FEC02FE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6DEC2BE-2760-46C1-8500-B5CAECDB5049</gtr:id><gtr:title>Oligonucleotide analogs as antiviral agents.</gtr:title><gtr:parentPublicationTitle>Current opinion in molecular therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00a5eca76151c76f54001f781d91b442"><gtr:id>00a5eca76151c76f54001f781d91b442</gtr:id><gtr:otherNames>Fabani MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1464-8431</gtr:issn><gtr:outcomeId>65F0D001605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEF0F46B-73D9-43B3-A779-36DF0EB4C736</gtr:id><gtr:title>In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn><gtr:outcomeId>auTfntcLWdA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>601135CF-21E6-497C-A33C-A6A21B1CCFC1</gtr:id><gtr:title>Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84858b1e9f1f73d623822d7a590fb2dd"><gtr:id>84858b1e9f1f73d623822d7a590fb2dd</gtr:id><gtr:otherNames>Torres AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>pm_14217_27_22070883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E75A36E-5792-4900-968A-ADC051F3C04C</gtr:id><gtr:title>Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50c6cbe2f1cdeadd4b847ef6210eb4de"><gtr:id>50c6cbe2f1cdeadd4b847ef6210eb4de</gtr:id><gtr:otherNames>Deuss PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>pm_14217_27_24105028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E255942D-256B-4B09-A766-E5218EFCF276</gtr:id><gtr:title>Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy.</gtr:title><gtr:parentPublicationTitle>Nucleic acid therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079cb700d5d8d3f1571cdabcb383b5d3"><gtr:id>079cb700d5d8d3f1571cdabcb383b5d3</gtr:id><gtr:otherNames>Shabanpoor F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2159-3337</gtr:issn><gtr:outcomeId>58b01fe20c40f8.44670383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A61E5C10-4C2B-4751-B77B-536E8AAC66AD</gtr:id><gtr:title>PNA-peptide conjugates as intracellular gene control agents.</gtr:title><gtr:parentPublicationTitle>Nucleic acids symposium series (2004)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f82799396794e89283a9b0507792aa31"><gtr:id>f82799396794e89283a9b0507792aa31</gtr:id><gtr:otherNames>Ivanova GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0261-3166</gtr:issn><gtr:outcomeId>7E26157B17B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E98A6B76-CDE0-4782-A5D4-1A036FEF6CE1</gtr:id><gtr:title>Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Journal of peptide science : an official publication of the European Peptide Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f8ea5ad67c4b4f190e884747933e20f"><gtr:id>0f8ea5ad67c4b4f190e884747933e20f</gtr:id><gtr:otherNames>Abes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1075-2617</gtr:issn><gtr:outcomeId>F92BC5B62DC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>100B4578-1F46-4AE4-BFE7-2459D706E644</gtr:id><gtr:title>2'-Hydrazine oligonucleotides: synthesis and efficient conjugation with aldehydes.</gtr:title><gtr:parentPublicationTitle>Nucleic acids symposium series (2004)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f914ce2548a1de7b5950d70d6d64473"><gtr:id>6f914ce2548a1de7b5950d70d6d64473</gtr:id><gtr:otherNames>Zatsepin TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0261-3166</gtr:issn><gtr:outcomeId>90F5B2A63D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2D0D2E1-9E3F-4583-A86A-14C9FB70010A</gtr:id><gtr:title>Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491e03b7abf9ad5daca18f66ee4a93f7"><gtr:id>491e03b7abf9ad5daca18f66ee4a93f7</gtr:id><gtr:otherNames>Abes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>07BC9691607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F12A68EC-006D-426D-B061-0C0072572261</gtr:id><gtr:title>Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491e03b7abf9ad5daca18f66ee4a93f7"><gtr:id>491e03b7abf9ad5daca18f66ee4a93f7</gtr:id><gtr:otherNames>Abes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>F2F3F291E59</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27165B22-1B83-4BA1-B814-E2563F3623E7</gtr:id><gtr:title>Cell-penetrating-peptide-based delivery of oligonucleotides: an overview.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f8ea5ad67c4b4f190e884747933e20f"><gtr:id>0f8ea5ad67c4b4f190e884747933e20f</gtr:id><gtr:otherNames>Abes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>904EE1BD3B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD46C92B-FDB4-4B4E-B117-684A9C58B611</gtr:id><gtr:title>Assessing the Delivery of Molecules to the Mitochondrial Matrix Using Click Chemistry.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/139964bcb1e0cbbf222efa9b6caf56e6"><gtr:id>139964bcb1e0cbbf222efa9b6caf56e6</gtr:id><gtr:otherNames>Hoogewijs K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>58b01fe266d088.91854412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8C9AC0F-9810-400C-9AC3-D2BEEF8771E6</gtr:id><gtr:title>Systematic screening of LNA/2'-O-methyl chimeric derivatives of a TAR RNA aptamer.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b90b8e268fc726a67b44dcf6f7807fa8"><gtr:id>b90b8e268fc726a67b44dcf6f7807fa8</gtr:id><gtr:otherNames>Di Primo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>BB3D1CE5064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1608E63D-2CC7-424A-B685-E9AB8CEEFE88</gtr:id><gtr:title>Chemical modifications to improve the cellular uptake of oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Current topics in medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbeee4784d2de83d8b206280866a236f"><gtr:id>cbeee4784d2de83d8b206280866a236f</gtr:id><gtr:otherNames>Debart F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1568-0266</gtr:issn><gtr:outcomeId>671A20D8649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13F98230-21EA-446A-9802-B8A54E379C4D</gtr:id><gtr:title>Overview of alternative oligonucleotide chemistries for exon skipping.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/304637c4027c4df2fa9160d8ad886688"><gtr:id>304637c4027c4df2fa9160d8ad886688</gtr:id><gtr:otherNames>Saleh AF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_14217_27_22454073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEBE3361-5DF5-4A6E-8E52-3729B48FE704</gtr:id><gtr:title>Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/068c70e545536ea9dee784649032d44f"><gtr:id>068c70e545536ea9dee784649032d44f</gtr:id><gtr:otherNames>Bestas B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>545b66734039e2.66264344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4C0A23E-744C-4DC6-9C72-B8F36FCB93FC</gtr:id><gtr:title>A chemical view of oligonucleotides for exon skipping and related drug applications.</gtr:title><gtr:parentPublicationTitle>Nucleic acid therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5cbf7dc26a737e3b68f235e753a64e8"><gtr:id>e5cbf7dc26a737e3b68f235e753a64e8</gtr:id><gtr:otherNames>J?rver P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2159-3337</gtr:issn><gtr:outcomeId>545b66bfd6f224.41533408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCC6A200-A5E2-47D1-A593-7017979ADE69</gtr:id><gtr:title>Applied RNAi. From Fundamental Research to Therapeutic Applications</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9111609af46b433fb26ed131a733e957"><gtr:id>9111609af46b433fb26ed131a733e957</gtr:id><gtr:otherNames>J?rver, P., Torres, A.G., and Gait, M.J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-1-908230-43-0</gtr:isbn><gtr:issn>Arbuthnot, P. and We</gtr:issn><gtr:outcomeId>545372e46c61e4.45433888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7986F78-4D11-4BF8-BBF8-9010B61E86BD</gtr:id><gtr:title>Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Nucleic acid therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34bd0ea1d9957a0111968a9d3c639cca"><gtr:id>34bd0ea1d9957a0111968a9d3c639cca</gtr:id><gtr:otherNames>O'Donovan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2159-3337</gtr:issn><gtr:outcomeId>56d9aa99cdfed4.68871712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A07DD9A-D78E-477C-8C9E-0739E4386718</gtr:id><gtr:title>Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/657260e5076ba6423d7ba111f3b75899"><gtr:id>657260e5076ba6423d7ba111f3b75899</gtr:id><gtr:otherNames>Betts CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5675e75c654eb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A25683D4-8E26-420A-A5C2-6A4CB8E945C5</gtr:id><gtr:title>Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ceef2a90e46a0e4368653e63abe06ba"><gtr:id>7ceef2a90e46a0e4368653e63abe06ba</gtr:id><gtr:otherNames>Malerba A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_14217_27_23250360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25E07186-AEFC-45A3-B3DD-BE26EA67CF70</gtr:id><gtr:title>MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection.</gtr:title><gtr:parentPublicationTitle>RNA (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84858b1e9f1f73d623822d7a590fb2dd"><gtr:id>84858b1e9f1f73d623822d7a590fb2dd</gtr:id><gtr:otherNames>Torres AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1355-8382</gtr:issn><gtr:outcomeId>bUuzMPYNifu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EAE25B3-3A3C-4244-83D5-3229DD5A6922</gtr:id><gtr:title>Efficient inhibition of miR-155 function in vivo by peptide nucleic acids.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00a5eca76151c76f54001f781d91b442"><gtr:id>00a5eca76151c76f54001f781d91b442</gtr:id><gtr:otherNames>Fabani MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>q6c9csMgXja</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC9B4723-E6AB-4A6F-B07B-AF7E56C7482C</gtr:id><gtr:title>Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Nucleic acid therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b77449ecd226659758ab7bbc3bd8eab9"><gtr:id>b77449ecd226659758ab7bbc3bd8eab9</gtr:id><gtr:otherNames>Burki U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2159-3337</gtr:issn><gtr:outcomeId>58b061115cfa25.41880456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>658C07E4-2E24-41ED-9973-02E76B7109C5</gtr:id><gtr:title>Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5dcceb96c14ac16b6386b86215cac484"><gtr:id>5dcceb96c14ac16b6386b86215cac484</gtr:id><gtr:otherNames>Betts C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_14217_27_23344180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2E634FF-C8BC-4A5D-975A-EF3C321D509E</gtr:id><gtr:title>Disulfide conjugation of peptides to oligonucleotides and their analogs.</gtr:title><gtr:parentPublicationTitle>Current protocols in nucleic acid chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7174c61d83c3ff6274bb831026dce87e"><gtr:id>7174c61d83c3ff6274bb831026dce87e</gtr:id><gtr:otherNames>Turner JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1934-9270</gtr:issn><gtr:outcomeId>F6F16BB8EE7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE34D4F1-8D6B-4546-9EEF-BC8C2AA0384A</gtr:id><gtr:title>Inhibition of HIV-1 replication by oligonucleotide analogues directed to the packaging signal and trans-activating response region.</gtr:title><gtr:parentPublicationTitle>Antiviral chemistry &amp; chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7ac551b97440fb564f7271a324fadf3"><gtr:id>d7ac551b97440fb564f7271a324fadf3</gtr:id><gtr:otherNames>Brown DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0956-3202</gtr:issn><gtr:outcomeId>4D766FBC738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73B3C217-9840-4C02-B570-BF2995F14485</gtr:id><gtr:title>Lipoplex and peptide-based strategies for the delivery of steric-block oligonucleotides.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f8e63adeded5cf8075178af124ad85f"><gtr:id>7f8e63adeded5cf8075178af124ad85f</gtr:id><gtr:otherNames>Resina S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>910B244E096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98742F6B-ED84-4FA8-B38C-B9FF365300C2</gtr:id><gtr:title>Tricyclo-DNA containing oligonucleotides as steric block inhibitors of human immunodeficiency virus type 1 tat-dependent trans-activation and HIV-1 infectivity.</gtr:title><gtr:parentPublicationTitle>Oligonucleotides</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/046e7a1192a14d70b68ca33d3ca39b7a"><gtr:id>046e7a1192a14d70b68ca33d3ca39b7a</gtr:id><gtr:otherNames>Ivanova G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1545-4576</gtr:issn><gtr:outcomeId>A52C02E5D95</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C98F4547-729F-4EF6-8030-C96E93F00468</gtr:id><gtr:title>Synthesis and splice-redirecting activity of branched, arginine-rich peptide dendrimer conjugates of peptide nucleic acid oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/304637c4027c4df2fa9160d8ad886688"><gtr:id>304637c4027c4df2fa9160d8ad886688</gtr:id><gtr:otherNames>Saleh AF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>UyhAwe6HSHe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F239AB9-2D2C-45C2-9C83-D64076F7BC1A</gtr:id><gtr:title>Anti-HIV activity of steric block oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/046e7a1192a14d70b68ca33d3ca39b7a"><gtr:id>046e7a1192a14d70b68ca33d3ca39b7a</gtr:id><gtr:otherNames>Ivanova G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>D925A4F1982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15C57800-8F32-48AB-B6EF-490CD58212F6</gtr:id><gtr:title>Synthesis and biological activity of phosphonoacetate- and thiophosphonoacetate-modified 2'-O-methyl oligoribonucleotides.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/726165331c6193c7f33d7ffc65bc7bd4"><gtr:id>726165331c6193c7f33d7ffc65bc7bd4</gtr:id><gtr:otherNames>Threlfall RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>pm_14217_27_22124653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC9CA15B-EA4B-4787-8581-DF8927F6CF96</gtr:id><gtr:title>Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f1b49f45e81425283cf5e9b6624031"><gtr:id>e0f1b49f45e81425283cf5e9b6624031</gtr:id><gtr:otherNames>Moschos SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>2540796FFC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9DBECAD-86EB-424C-A55F-5D94B0AD8860</gtr:id><gtr:title>RNA targeting in cells by peptide conjugates of peptide nucleic acids (PNA)</gtr:title><gtr:parentPublicationTitle>Collection Symposium Series</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e01ca534bddcbd53f5333bb3434c1d08"><gtr:id>e01ca534bddcbd53f5333bb3434c1d08</gtr:id><gtr:otherNames>Ivanova GD, Arzumanov AA, Turner JJ, Fabani MM, Abes R, Lebleu B , Gait MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>4FCE125D42A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91083F54-1A8B-4FB5-854A-2196BBF5686E</gtr:id><gtr:title>Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>f1LExCAtunb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECDCDF0B-DC39-42D4-B64B-D20192347397</gtr:id><gtr:title>Synthesis of oligo-2'-O-methylribonucleotides containing a-amino acid residues in 2'-position</gtr:title><gtr:parentPublicationTitle>Russian Chemical Bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bd78fdd41055955e34ad01688ecfbce"><gtr:id>8bd78fdd41055955e34ad01688ecfbce</gtr:id><gtr:otherNames>Kazanova E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>DA5C46D0554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B2B508A-A2C6-42FD-BF91-CE81E21C057E</gtr:id><gtr:title>Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37f48950ac754a3c97a85fecf4e1d7e4"><gtr:id>37f48950ac754a3c97a85fecf4e1d7e4</gtr:id><gtr:otherNames>Coenen-Stass AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d9aa995c8bf7.61036895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAA75127-0BBF-409A-AE0D-4723C40C3987</gtr:id><gtr:title>A peptide-based dendrimer that enhances the splice-redirecting activity of PNA conjugates in cells.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac2aa3bd5cf95d5ff7ca9acfd2f90e0c"><gtr:id>ac2aa3bd5cf95d5ff7ca9acfd2f90e0c</gtr:id><gtr:otherNames>Hassane FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>FBADD4B5EB7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1A40FD5-CA94-42C1-B8F8-C905DA2BBF2D</gtr:id><gtr:title>Delivery of therapeutic oligonucleotides with cell penetrating peptides.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e35eaaadb1f009aa8b423537ae3b6a03"><gtr:id>e35eaaadb1f009aa8b423537ae3b6a03</gtr:id><gtr:otherNames>Boisgu?rin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>56d9aa990fe0a1.70149378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A843F4CC-BEA5-4C89-8232-847F1A1A527A</gtr:id><gtr:title>Splice redirection as a convenient assay to monitor CPP-ON efficiency and mechanism.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f8ea5ad67c4b4f190e884747933e20f"><gtr:id>0f8ea5ad67c4b4f190e884747933e20f</gtr:id><gtr:otherNames>Abes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>n3XMhtKvJd2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E153A5B5-6935-4041-AB2F-9FFF90288D4D</gtr:id><gtr:title>Cell penetrating peptide conjugates of steric block oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76998bd9c10fc4a590e35a588aef5f46"><gtr:id>76998bd9c10fc4a590e35a588aef5f46</gtr:id><gtr:otherNames>Lebleu B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>0F05D2675F6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F952832A-534F-4420-BA12-6B4DDD9BC0AA</gtr:id><gtr:title>Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f63c6b2fcac189b2b9a8f58f72925bb4"><gtr:id>f63c6b2fcac189b2b9a8f58f72925bb4</gtr:id><gtr:otherNames>Hammond SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58b01fe2447e19.41359428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1AAFEE6-6AB9-443D-8F9A-ECE25A7A9309</gtr:id><gtr:title>RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA.</gtr:title><gtr:parentPublicationTitle>Blood cells, molecules &amp; diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7174c61d83c3ff6274bb831026dce87e"><gtr:id>7174c61d83c3ff6274bb831026dce87e</gtr:id><gtr:otherNames>Turner JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1079-9796</gtr:issn><gtr:outcomeId>5342748F5B6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD09E66F-4252-4E23-9A07-112E3734B351</gtr:id><gtr:title>RNA-targeted splice-correction therapy for neuromuscular disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfeee30751678f5126da4059b895c3ce"><gtr:id>dfeee30751678f5126da4059b895c3ce</gtr:id><gtr:otherNames>Wood MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>GJ6uxti1vNC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D710C647-BFB2-4503-96D4-9756E5A95246</gtr:id><gtr:title>Peptide-based in vivo delivery agents for oligonucleotides and siRNA.</gtr:title><gtr:parentPublicationTitle>Nucleic acid therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f92c8ba0cc0f729cb30ca77776bbc6c4"><gtr:id>f92c8ba0cc0f729cb30ca77776bbc6c4</gtr:id><gtr:otherNames>Coursindel T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2159-3337</gtr:issn><gtr:outcomeId>pm_14217_27_22409235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D468C46-A83B-4CA1-9FAE-39B11FA21EED</gtr:id><gtr:title>Nucleic acids: new life, new materials.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a57cb3577cc4d90a7472615e32dd95c"><gtr:id>4a57cb3577cc4d90a7472615e32dd95c</gtr:id><gtr:otherNames>Gait MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>545b6606452d35.20233906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2075E0DB-499B-42AD-A956-169ADFB6DE20</gtr:id><gtr:title>Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079cb700d5d8d3f1571cdabcb383b5d3"><gtr:id>079cb700d5d8d3f1571cdabcb383b5d3</gtr:id><gtr:otherNames>Shabanpoor F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>56d9aa98bf0468.77388742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DAB95D0-0C97-45F3-A0B0-B909D901E711</gtr:id><gtr:title>Cell penetrating peptides: overview and applications to the delivery of oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64068b7ac671519a138f056749809b06"><gtr:id>64068b7ac671519a138f056749809b06</gtr:id><gtr:otherNames>Said Hassane F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn><gtr:outcomeId>siKWdWkcutz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>358D4A45-928A-4401-A19C-A69B6D859D0E</gtr:id><gtr:title>Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56d9aa99a6a559.08644094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>590A4C49-82A2-42E5-B031-D54E7F27EE33</gtr:id><gtr:title>Preparation of 2'-hydrazino oligonucleotides and their reaction with aldehydes and 1,3-diketones.</gtr:title><gtr:parentPublicationTitle>Nucleosides, nucleotides &amp; nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f914ce2548a1de7b5950d70d6d64473"><gtr:id>6f914ce2548a1de7b5950d70d6d64473</gtr:id><gtr:otherNames>Zatsepin TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-7770</gtr:issn><gtr:outcomeId>90C00197EA5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>484F8189-EBD3-4F8A-9379-52F031F3B79C</gtr:id><gtr:title>Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_14217_27_23344181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DA65569-350A-4CED-A05C-739600081B65</gtr:id><gtr:title>miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates.</gtr:title><gtr:parentPublicationTitle>RNA (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00a5eca76151c76f54001f781d91b442"><gtr:id>00a5eca76151c76f54001f781d91b442</gtr:id><gtr:otherNames>Fabani MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1355-8382</gtr:issn><gtr:outcomeId>C487DBCE4B8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BF61461-90AA-4F5B-B7DC-BB03E2E99F94</gtr:id><gtr:title>Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>dRZCBrKox2e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CA2C22A-5033-4B20-9342-CE24D2D027F0</gtr:id><gtr:title>Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f82799396794e89283a9b0507792aa31"><gtr:id>f82799396794e89283a9b0507792aa31</gtr:id><gtr:otherNames>Ivanova GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>25DCFBFD942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CC93E98-009C-4C15-9363-8B718189DFDB</gtr:id><gtr:title>Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: chemistry and cell delivery.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7174c61d83c3ff6274bb831026dce87e"><gtr:id>7174c61d83c3ff6274bb831026dce87e</gtr:id><gtr:otherNames>Turner JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>EF77599FBF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BB432FD-6CF0-46B1-8860-E407F449FD14</gtr:id><gtr:title>Human beta-synuclein rendered fibrillogenic by designed mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63d933ac4d7cc10c11a493876994bb7d"><gtr:id>63d933ac4d7cc10c11a493876994bb7d</gtr:id><gtr:otherNames>Zibaee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>qYLRHnPWxe8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0960C08B-CBE6-4119-AD50-84A037117830</gtr:id><gtr:title>Exploiting cell surface thiols to enhance cellular uptake.</gtr:title><gtr:parentPublicationTitle>Trends in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84858b1e9f1f73d623822d7a590fb2dd"><gtr:id>84858b1e9f1f73d623822d7a590fb2dd</gtr:id><gtr:otherNames>Torres AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-7799</gtr:issn><gtr:outcomeId>pm_14217_27_22260747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F13B609-5F6A-42DB-8C23-28790FDDF87B</gtr:id><gtr:title>Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079cb700d5d8d3f1571cdabcb383b5d3"><gtr:id>079cb700d5d8d3f1571cdabcb383b5d3</gtr:id><gtr:otherNames>Shabanpoor F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>pm_14217_27_24064913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D615785C-8AF9-476B-8B2C-BB6DCCDDBA48</gtr:id><gtr:title>Solid-Phase Synthesis of Difficult Purine-Rich PNAs through Selective Hmb Incorporation: Application to the Total Synthesis of Cell Penetrating Peptide-PNAs.</gtr:title><gtr:parentPublicationTitle>Frontiers in chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98489cab6554e437e53132baef0b5025"><gtr:id>98489cab6554e437e53132baef0b5025</gtr:id><gtr:otherNames>Tailhades J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2296-2646</gtr:issn><gtr:outcomeId>5a9979860e4a27.98100839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21570699-5B2F-4D84-8B5A-F2C1C79C1FE5</gtr:id><gtr:title>Diaphragm rescue alone prevents heart dysfunction in dystrophic mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/321e063cceeeaa3dbaebdbfe5918c9c4"><gtr:id>321e063cceeeaa3dbaebdbfe5918c9c4</gtr:id><gtr:otherNames>Crisp A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>GdRgNkdkvrQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FF6D959-A970-4D06-9DCB-AD9FD4F99FA9</gtr:id><gtr:title>MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7174c61d83c3ff6274bb831026dce87e"><gtr:id>7174c61d83c3ff6274bb831026dce87e</gtr:id><gtr:otherNames>Turner JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>1E2A6C0847E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32CD57AF-8934-41EC-829A-6E0961DD6A8B</gtr:id><gtr:title>In Vitro Assays to Assess Exon Skipping in Duchenne Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92d94b4f5e24cb26c4871b96fa84652e"><gtr:id>92d94b4f5e24cb26c4871b96fa84652e</gtr:id><gtr:otherNames>Boisguerin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56d9aa99831506.22383229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48B6C1F5-73BC-4C4C-8338-0DFA9FAF6CD0</gtr:id><gtr:title>Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents.</gtr:title><gtr:parentPublicationTitle>Artificial DNA, PNA &amp; XNA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84858b1e9f1f73d623822d7a590fb2dd"><gtr:id>84858b1e9f1f73d623822d7a590fb2dd</gtr:id><gtr:otherNames>Torres AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1949-095X</gtr:issn><gtr:outcomeId>pm_14217_27_22567190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>884DE8AF-B067-42A5-8740-04355A648947</gtr:id><gtr:title>Steric block high affinity oligonucleotide analogues: a new tool for mapping RNA-protein binding sites.</gtr:title><gtr:parentPublicationTitle>Nucleosides, nucleotides &amp; nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57ce83deb2398a489b9544f192ed396b"><gtr:id>57ce83deb2398a489b9544f192ed396b</gtr:id><gtr:otherNames>Brown D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-7770</gtr:issn><gtr:outcomeId>681DF49DE14</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14B153C4-2B21-4033-B6AD-BA7620E591B1</gtr:id><gtr:title>Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491e03b7abf9ad5daca18f66ee4a93f7"><gtr:id>491e03b7abf9ad5daca18f66ee4a93f7</gtr:id><gtr:otherNames>Abes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>BC50F005C0C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5ED0AC0-1004-44E5-B355-7AB58839E25C</gtr:id><gtr:title>ClickIn: a flexible protocol for quantifying mitochondrial uptake of nucleobase derivatives.</gtr:title><gtr:parentPublicationTitle>Interface focus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/139964bcb1e0cbbf222efa9b6caf56e6"><gtr:id>139964bcb1e0cbbf222efa9b6caf56e6</gtr:id><gtr:otherNames>Hoogewijs K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2042-8898</gtr:issn><gtr:outcomeId>58b0215464cf68.75788432</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U105178803</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8EA3EC93-8E9C-482F-8121-C6C8413D9B6D</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.3  Chemical and physical sciences</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>